Total Payments
$1.5M
2024 Payments
$189,948
Companies
24
Transactions
1,384
Medicare Patients
1,239
Medicare Billing
$87,086
Payment Breakdown by Category
Other$1.1M (71.9%)
Travel$209,953 (14.1%)
Consulting$170,114 (11.4%)
Food & Beverage$28,480 (1.9%)
Research$10,001 (0.7%)
Education$920.71 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.1M | 363 | 70.6% |
| Travel and Lodging | $209,953 | 502 | 14.1% |
| Consulting Fee | $170,114 | 56 | 11.4% |
| Food and Beverage | $28,480 | 420 | 1.9% |
| Honoraria | $16,050 | 5 | 1.1% |
| Unspecified | $10,001 | 2 | 0.7% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $3,000 | 1 | 0.2% |
| Education | $920.71 | 34 | 0.1% |
| Grant | $508.00 | 1 | 0.0% |
Payments by Type
General
$1.5M
1,382 transactions
Research
$10,001
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $509,668 | 473 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $391,254 | 361 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $266,121 | 196 | $0 (2019) |
| Amarin Pharma Inc. | $94,909 | 109 | $0 (2023) |
| Esperion Therapeutics, Inc. | $72,562 | 63 | $0 (2024) |
| Alexion Pharmaceuticals, Inc. | $28,633 | 56 | $0 (2020) |
| Merck Sharp & Dohme LLC | $19,607 | 16 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $17,951 | 24 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $17,568 | 27 | $0 (2024) |
| Aegerion Pharmaceuticals, Inc. | $14,949 | 7 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $189,948 | 179 | Regeneron Healthcare Solutions, Inc. ($93,819) |
| 2023 | $136,491 | 143 | Regeneron Healthcare Solutions, Inc. ($79,922) |
| 2022 | $99,104 | 105 | Regeneron Healthcare Solutions, Inc. ($37,144) |
| 2021 | $95,800 | 68 | Amgen Inc. ($35,177) |
| 2020 | $88,826 | 78 | Amgen Inc. ($49,843) |
| 2019 | $264,091 | 255 | Amgen Inc. ($108,876) |
| 2018 | $335,602 | 281 | Amgen Inc. ($97,685) |
| 2017 | $283,832 | 275 | SANOFI-AVENTIS U.S. LLC ($97,823) |
All Payment Transactions
1,384 individual payment records from CMS Open Payments — Page 1 of 56
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | Chiesi USA, Inc. | JUXTAPID (Drug) | Food and Beverage | Cash or cash equivalent | $121.14 | General |
| Category: HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA | ||||||
| 12/10/2024 | Regeneron Pharmaceuticals, Inc. | EVKEEZA (Biological) | Food and Beverage | In-kind items and services | $72.74 | General |
| Category: CARDIOVASCULAR AND METABOLISM | ||||||
| 12/06/2024 | Regeneron Pharmaceuticals, Inc. | EVKEEZA (Biological) | Consulting Fee | Cash or cash equivalent | $5,484.00 | General |
| Category: CARDIOVASCULAR AND METABOLISM | ||||||
| 12/06/2024 | Regeneron Pharmaceuticals, Inc. | EVKEEZA (Biological) | Consulting Fee | Cash or cash equivalent | $1,828.00 | General |
| Category: CARDIOVASCULAR AND METABOLISM | ||||||
| 12/06/2024 | Regeneron Pharmaceuticals, Inc. | EVKEEZA (Biological) | Consulting Fee | Cash or cash equivalent | $914.00 | General |
| Category: CARDIOVASCULAR AND METABOLISM | ||||||
| 11/15/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $51.28 | General |
| Category: Cardiology | ||||||
| 11/05/2024 | Merck Sharp & Dohme LLC | LAGEVRIO (Drug) | Food and Beverage | In-kind items and services | $20.49 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 10/17/2024 | Regeneron Healthcare Solutions, Inc. | EVKEEZA (Biological) | Travel and Lodging | In-kind items and services | $188.78 | General |
| Category: CARDIOVASCULAR AND METABOLISM | ||||||
| 10/17/2024 | Regeneron Healthcare Solutions, Inc. | — | Travel and Lodging | In-kind items and services | $162.20 | General |
| 10/17/2024 | Regeneron Healthcare Solutions, Inc. | EVKEEZA (Biological) | Travel and Lodging | In-kind items and services | $124.96 | General |
| Category: CARDIOVASCULAR AND METABOLISM | ||||||
| 10/17/2024 | Regeneron Healthcare Solutions, Inc. | EVKEEZA (Biological) | Travel and Lodging | In-kind items and services | $106.25 | General |
| Category: CARDIOVASCULAR AND METABOLISM | ||||||
| 10/17/2024 | Regeneron Healthcare Solutions, Inc. | — | Travel and Lodging | In-kind items and services | $90.96 | General |
| 10/17/2024 | Regeneron Healthcare Solutions, Inc. | EVKEEZA (Biological) | Food and Beverage | In-kind items and services | $47.06 | General |
| Category: CARDIOVASCULAR AND METABOLISM | ||||||
| 10/17/2024 | Regeneron Healthcare Solutions, Inc. | EVKEEZA (Biological) | Food and Beverage | In-kind items and services | $17.75 | General |
| Category: CARDIOVASCULAR AND METABOLISM | ||||||
| 10/17/2024 | Regeneron Healthcare Solutions, Inc. | — | Food and Beverage | In-kind items and services | $14.16 | General |
| 10/17/2024 | Regeneron Healthcare Solutions, Inc. | — | Food and Beverage | In-kind items and services | $9.81 | General |
| 10/17/2024 | Regeneron Healthcare Solutions, Inc. | — | Food and Beverage | In-kind items and services | $4.99 | General |
| 10/16/2024 | Lilly USA, LLC | MOUNJARO (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $20.00 | General |
| Category: Diabetes | ||||||
| 09/27/2024 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $47.77 | General |
| 09/25/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $18.95 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/24/2024 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $66.50 | General |
| 09/17/2024 | Regeneron Healthcare Solutions, Inc. | EVKEEZA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $8,840.00 | General |
| Category: CARDIOVASCULAR AND METABOLISM | ||||||
| 09/14/2024 | Esperion Therapeutics, Inc. | NEXLIZET (Drug), NEXLETOL | Travel and Lodging | In-kind items and services | $310.85 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 09/14/2024 | Esperion Therapeutics, Inc. | NEXLIZET (Drug), NEXLETOL | Travel and Lodging | In-kind items and services | $267.95 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 09/14/2024 | Esperion Therapeutics, Inc. | NEXLIZET (Drug), NEXLETOL | Travel and Lodging | In-kind items and services | $255.00 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | NOVARTIS PHARMACEUTICALS CORPORATION | $9,700 | 1 |
| Perspectives on New Guidelines for Treating Dyslipidemia and Managing Cardiovascular Risk | Amgen Inc. | $300.55 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 241 | 318 | $50,712 | $18,814 |
| 2022 | 6 | 316 | 404 | $53,455 | $21,157 |
| 2021 | 7 | 326 | 449 | $57,115 | $22,591 |
| 2020 | 10 | 356 | 484 | $59,519 | $24,524 |
Total Patients
1,239
Total Services
1,655
Medicare Billing
$87,086
Procedure Codes
28
All Medicare Procedures & Services
28 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 71 | 89 | $22,250 | $8,478 | 38.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 80 | 125 | $21,375 | $7,427 | 34.7% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 22 | 30 | $3,150 | $1,290 | 41.0% |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2023 | 12 | 12 | $1,464 | $893.04 | 61.0% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 56 | 62 | $2,473 | $725.58 | 29.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 82 | 107 | $26,750 | $11,340 | 42.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 72 | 103 | $17,613 | $6,844 | 38.9% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 20 | 23 | $2,415 | $1,044 | 43.2% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2022 | 63 | 72 | $2,871 | $894.34 | 31.1% |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2022 | 11 | 11 | $1,342 | $772.75 | 57.6% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 68 | 88 | $2,464 | $261.78 | 10.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 73 | 98 | $24,458 | $10,205 | 41.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 76 | 110 | $18,810 | $8,135 | 43.2% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 14 | 14 | $5,291 | $1,822 | 34.4% |
| 90662 | Vaccine for influenza for injection into muscle, split virus, preservation free | Office | 2021 | 15 | 15 | $1,800 | $978.90 | 54.4% |
| 93000 | Routine ekg using at least 12 leads including interpretation and report | Office | 2021 | 56 | 61 | $2,433 | $716.27 | 29.4% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2021 | 75 | 134 | $3,752 | $394.10 | 10.5% |
| G0008 | Administration of influenza virus vaccine | Office | 2021 | 17 | 17 | $570.80 | $339.83 | 59.5% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 85 | 159 | $27,189 | $10,749 | 39.5% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 51 | 53 | $13,227 | $4,886 | 36.9% |
| 90670 | Pneumococcal vaccine for injection into muscle | Office | 2020 | 13 | 13 | $3,250 | $2,992 | 92.1% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 12 | 12 | $4,536 | $1,831 | 40.4% |
| 90662 | Vaccine for influenza for injection into muscle | Office | 2020 | 18 | 18 | $2,160 | $1,098 | 50.8% |
| 99212 | Established patient office or other outpatient visit, typically 10 minutes | Office | 2020 | 17 | 24 | $2,516 | $1,033 | 41.0% |
| 93000 | Routine ekg using at least 12 leads including interpretation and report | Office | 2020 | 48 | 51 | $2,034 | $760.57 | 37.4% |
About Dr. James Underberg, MD
Dr. James Underberg, MD is a Internal Medicine healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/08/2005. The National Provider Identifier (NPI) number assigned to this provider is 1538167127.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. James Underberg, MD has received a total of $1.5M in payments from pharmaceutical and medical device companies, with $189,948 received in 2024. These payments were reported across 1,384 transactions from 24 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.1M).
As a Medicare-enrolled provider, Underberg has provided services to 1,239 Medicare beneficiaries, totaling 1,655 services with total Medicare billing of $87,086. Data is available for 4 years (2020–2023), covering 28 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Location New York, NY
- Active Since 07/08/2005
- Last Updated 01/15/2019
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1538167127
Products in Payments
- Repatha (Biological) $497,666
- PRALUENT (Drug) $252,754
- EVKEEZA (Biological) $227,524
- PRALUENT ALIROCUMAB INJECTION (Biological) $132,706
- Vascepa (Drug) $94,909
- NEXLIZET (Drug) $63,871
- PRALUENT (Biological) $33,672
- LEQVIO (Drug) $17,951
- KYNAMRO (Drug) $14,347
- NO PRODUCT DISCUSSED (Drug) $13,367
- Livalo (Drug) $12,776
- JUXTAPID (Drug) $11,788
- NEXLETOL (Drug) $8,691
- Kanuma (Drug) $8,157
- EPANOVA (Drug) $2,617
- JARDIANCE (Drug) $1,706
- Juxtapid (Drug) $1,100
- FARXIGA (Drug) $1,074
- Otezla (Drug) $125.00
- MOUNJARO (Drug) $67.65
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in New York
Dr. Stephen Saletan, M.d, M.D
Internal Medicine — Payments: $2.7M
Internal Medicine $2.7M
Michael Schuster, Md, MD
Internal Medicine — Payments: $2.1M
Internal Medicine $2.1M
Dr. Ziad Ali, Md Dphil, MD DPHIL
Internal Medicine — Payments: $1.7M
Internal Medicine $1.7M
Dr. Ricky Hsu, Md, MD
Internal Medicine — Payments: $1.2M
Internal Medicine $1.2M
Gail Roboz, Md, MD
Internal Medicine — Payments: $1.1M
Internal Medicine $1.1M
Gary Slatko, Md, MD
Internal Medicine — Payments: $910,320
Internal Medicine $910,320